Huntington National Bank’s SCIELE PHARMA INC COM STK SCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31 | Hold |
1
| – | – | ﹤0.01% | 3218 |
|
|
2025
Q4 | $31 | Hold |
1
| – | – | ﹤0.01% | 3128 |
|
|
2025
Q3 | $31 | Hold |
1
| – | – | ﹤0.01% | 3183 |
|
|
2025
Q2 | $31 | Hold |
1
| – | – | ﹤0.01% | 3207 |
|
|
2025
Q1 | $31 | Hold |
1
| – | – | ﹤0.01% | 3239 |
|
|
2024
Q4 | $31 | Hold |
1
| – | – | ﹤0.01% | 3263 |
|
|
2024
Q3 | $31 | Hold |
1
| – | – | ﹤0.01% | 3250 |
|
|
2024
Q2 | $31 | Hold |
1
| – | – | ﹤0.01% | 3212 |
|
|
2024
Q1 | $31 | Hold |
1
| – | – | ﹤0.01% | 3068 |
|
|
2023
Q4 | $31 | Hold |
1
| – | – | ﹤0.01% | 2960 |
|
|
2023
Q3 | $31 | Hold |
1
| – | – | ﹤0.01% | 2944 |
|
|
2023
Q2 | $31 | Hold |
1
| – | – | ﹤0.01% | 2919 |
|
|
2023
Q1 | $31 | Hold |
1
| – | – | ﹤0.01% | 2770 |
|
|
2022
Q4 | $31 | Hold |
1
| – | – | ﹤0.01% | 2635 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 2962 |
|
|
2022
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 2965 |
|
|
2022
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 2891 |
|
|
2021
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 2818 |
|
|
2021
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 2542 |
|
|
2021
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 2430 |
|
|
2021
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 2320 |
|
|
2020
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 2297 |
|
|
2020
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 2243 |
|
|
2020
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 2256 |
|
|
2020
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 2351 |
|
|
2019
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 2361 |
|
|
2019
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 2267 |
|
|
2019
Q2 | $0 | Buy |
+1
| New | – | ﹤0.01% | 2301 |
|
|
2019
Q1 | – | Sell |
-1
| Closed | – | – | 2299 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 2353 |
|
|
2018
Q3 | $0 | Buy |
+1
| New | – | ﹤0.01% | 2339 |
|
Huntington National Bank's SCRX Position: Q1 2026 in Review
Huntington National Bank held its SCIELE PHARMA INC COM STK (SCRX) position steady in Q1 2026 at 1 share worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #3218.
Huntington National Bank first reported a position in SCRX in Q3 2018 and has held it in 30 quarters since. 1 fund tracked by Wall St. Rank holds SCRX as of Q1 2026.
- Huntington National Bank held 1 share of SCIELE PHARMA INC COM STK worth $31 as of Q1 2026.
- Huntington National Bank left its SCIELE PHARMA INC COM STK share count unchanged in Q1 2026.
- SCIELE PHARMA INC COM STK made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #3218 holding.
- Huntington National Bank first reported a position in SCIELE PHARMA INC COM STK in Q3 2018 and has held it in 30 quarters since.
- 1 fund tracked by Wall St. Rank held SCIELE PHARMA INC COM STK as of Q1 2026.
Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.